Tests Truvada, an antiviral drug, against Epstein-Barr virus in multiple sclerosis
Tests whether the antiviral Truvada lowers Epstein-Barr virus levels in adults with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Effects of Antiviral Therapies on Epstein-Barr Virus Replication
Key facts
- Where
- Boston, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Massachusetts General HospitalBoston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT05957913
- Record updated
- 14 July 2026
- Original description
This research study is being performed to find out if Truvada (tenofovir/emtricitabine), an antiviral drug with activity against the Epstein Barr virus (EBV), can reduce EBV levels in saliva and blood in people with multiple sclerosis (MS). A second goal is to find out if Truvada (tenofovir/ emtricitabine) is safe and tolerable in people with MS.Read full original descriptionShow less
Effects of Antiviral Therapies on Epstein-Barr Virus Replication
This research study is being performed to find out if Truvada (tenofovir/emtricitabine), an antiviral drug with activity against the Epstein Barr virus (EBV), can reduce EBV levels in saliva and blood in people with multiple sclerosis (MS). A second goal is to find out if Truvada (tenofovir/ emtricitabine) is safe and tolerable in people with MS.
Inclusion: Provision of signed and dated informed consent form; Stated willingness and ability to comply with all study procedures and availability for the duration of the study; Age: 18+; Established diagnosis of multiple sclerosis; Evidence of Epstein Barr virus (EBV) infection by serological testing for EBV antibodies antibodies (subjects will have EBV testing performed at the pre-screening visit and if serologies are negative, the subjects will be removed from the study).
Exclusion: Previous treatment with Truvada or Descovy; Unknown HIV status (subjects must have completed HIV antigen/antibody and viral load testing within the prior 6 months to being enrolled or have the testing completed at the pre-screening visit); Active or latent hepatitis B (HBV) (subjects must have completed HBV serologies - HbsAg, anti-HBs, and anti-HBc - within the prior 6 months to being enrolled or have the testing completed at the pre-screening visit); Taking a medication with known interactions with Truvada including but not limited to: Acyclovir, valacyclovir, adefovir, cabozantinib, carbamazepine, cidofovir, cladribine, cobicistat, diclofenac, multiple non-steroidal antiinflammatories (NSAIDs) or chronic high dose NSAIDs, fosphenytoin or phenytoin, ganciclovir, valganciclovir, oxcarbazepine, phenobarbital, primidone, rifabutin, rifampin, rifapentine, sofosbuvir, tipranavir, or other drugs that significantly affect renal function; Current treatment with drugs known to affect EBV replication as listed below: Acyclovir, valacyclovir, ganciclovir, valganciclovir, famciclovir, teriflunomide, interferon; Known allergic reactions to components of Truvada; Current symptoms of severe, progressive, or uncontrolled renal, hematologic, gastrointestinal, pulmonary, cardiac, or neurologic disease, or other medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study; Any history of bone fractures not explained by trauma; Creatinine clearance (CrCl) <75mL/min, as calculated by the Cockcroft-Gault equation; Urine dipstick for protein and glucose, excluding values of "1 +" or greater; Pregnancy or lactation; Confirmed Grade 2 or greater hypophosphatemia; Any Grade 2 or greater toxicity on screening tests and assessments.